143 related articles for article (PubMed ID: 35850360)
1. Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas.
Gkountakos A; Mafficini A; Lou E; Malleo G; Salvia R; Calicchia M; Silvestris N; Racila E; Amin K; Veronese N; Brunetti O; Antonini P; Ingravallo G; Mattiolo P; Saponaro C; Nappo F; Simbolo M; Bariani E; Lonardi S; Fassan M; Milella M; Lawlor RT; Scarpa A; Luchini C
Hum Pathol; 2022 Oct; 128():124-133. PubMed ID: 35850360
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
4. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract][Full Text] [Related]
5. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.
Hrudka J; Kalinová M; Ciprová V; Moravcová J; Dvořák R; Matěj R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542259
[TBL] [Abstract][Full Text] [Related]
6. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.
Lenkiewicz E; Malasi S; Hogenson TL; Flores LF; Barham W; Phillips WJ; Roesler AS; Chambers KR; Rajbhandari N; Hayashi A; Antal CE; Downes M; Grandgenett PM; Hollingsworth MA; Cridebring D; Xiong Y; Lee JH; Ye Z; Yan H; Hernandez MC; Leiting JL; Evans RM; Ordog T; Truty MJ; Borad MJ; Reya T; Von Hoff DD; Fernandez-Zapico ME; Barrett MT
Cancer Res; 2020 Oct; 80(20):4324-4334. PubMed ID: 32928922
[TBL] [Abstract][Full Text] [Related]
7. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y; Jin J; Ji Y; Zhang J; Fu N; Chen M; Wang J; Qin K; Jiang Y; Cheng D; Deng X; Shen B
J Transl Med; 2023 Dec; 21(1):872. PubMed ID: 38037073
[TBL] [Abstract][Full Text] [Related]
8. Molecular characteristics of early-onset pancreatic ductal adenocarcinoma.
Debernardi S; Liszka L; Ntala C; Steiger K; Esposito I; Carlotti E; Baker AM; McDonald S; Graham T; Dmitrovic B; Feakins RM; Crnogorac-Jurcevic T
Mol Oncol; 2024 Mar; 18(3):677-690. PubMed ID: 38145461
[TBL] [Abstract][Full Text] [Related]
9. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
Ramakrishnan G; Parajuli P; Singh P; Friend C; Hurwitz E; Prunier C; Razzaque MS; Xu K; Atfi A
Cell Rep; 2022 Nov; 41(6):111623. PubMed ID: 36351408
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic signaling pathways in pancreatic ductal adenocarcinoma.
Agrawal R; Natarajan KN
Adv Cancer Res; 2023; 159():251-283. PubMed ID: 37268398
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.
Moser R; Annis J; Nikolova O; Whatcott C; Gurley K; Mendez E; Moran-Jones K; Dorrell C; Sears RC; Kuo C; Han H; Biankin A; Grandori C; Von Hoff DD; Kemp CJ
Cancer Res; 2022 Sep; 82(18):3375-3393. PubMed ID: 35819261
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis IA; Digklia A
Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
14. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma.
Detlefsen S; Boldt HB; Burton M; Thomsen MM; Rasmussen LG; Ørbeck SV; Pfeiffer P; Mortensen MB; de Stricker K
Hum Pathol; 2023 Dec; 142():68-80. PubMed ID: 37977512
[TBL] [Abstract][Full Text] [Related]
15. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract][Full Text] [Related]
16. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer.
Xu ZH; Wang WQ; Liu L; Lou WH
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188751. PubMed ID: 35732240
[TBL] [Abstract][Full Text] [Related]
17. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
[TBL] [Abstract][Full Text] [Related]
18. Ecoevolutionary biology of pancreatic ductal adenocarcinoma.
Raja Arul GL; Toruner MD; Gatenby RA; Carr RM
Pancreatology; 2022 Sep; 22(6):730-740. PubMed ID: 35821188
[TBL] [Abstract][Full Text] [Related]
19. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients.
Huerta M; Martín-Arana J; Gimeno-Valiente F; Carbonell-Asins JA; García-Micó B; Martínez-Castedo B; Robledo-Yagüe F; Camblor DG; Fleitas T; García Bartolomé M; Alfaro-Cervelló C; Garcés-Albir M; Dorcaratto D; Muñoz-Forner E; Seguí V; Mora-Oliver I; Gambardella V; Roselló S; Sabater L; Roda D; Cervantes A; Tarazona N
Transl Res; 2024 Sep; 271():105-115. PubMed ID: 38782356
[TBL] [Abstract][Full Text] [Related]
20. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
Waters AM; Der CJ
Cold Spring Harb Perspect Med; 2018 Sep; 8(9):. PubMed ID: 29229669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
